low-dose tenecteplase intravenous thrombolysis

ApprovedSmall molecule

low-dose tenecteplase intravenous thrombolysis is one of 33 small molecule programs targeting Acute Ischemic Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Ischemic StrokeRecruiting

Ischemic StrokeActive, not recruiting

Acute Ischemic StrokeApproved

Recruiting

Ischemic StrokeApproved

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

low-dose tenecteplase intravenous thrombolysis

SSouthwest Hospital, China

Approved

1 2

Proamatine

Takeda

Preclinical

2 3

Repatha

Amgen

Preclinical

2 4

Tylenol

KKenvue Brands

Preclinical

1 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedRecruiting

Acute Ischemic Stroke

NCT07294209

Clinical

Trials by Indication[1]

Acute Ischemic Stroke1 trial

Efficacy and Safety of Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients: A Prospective, Multicenter, Randomized Controlled Study

Recruiting·SSouthwest Hospital, China·Approved·NCT07294209·798 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for low-dose tenecteplase intravenous thrombolysis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — low-dose tenecteplase intravenous thrombolysis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for low-dose tenecteplase intravenous thrombolysis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southwest Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSouthwest Hospital, China

low-dose tenecteplase intravenous thrombolysis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News